logo
  

Sartorius 9M Profit, Orders Climb; Lifts FY20 Outlook; Backs FY25 View - Quick Facts

Sartorius AG (SDMHF.PK), a German laboratory and pharmaceutical equipment provider, reported Tuesday that its nine-month earnings and sales grew in significant double-digit rates with high demand for nearly entire product range.

Net profit for the Group increased 37.9 percent to 211.2 million euros from last year's 153.2 million euros. Consolidated earnings per ordinary share were 3.08 euros, up from previous year's 2.23 euros, and per preference share were 3.09 euros, up from last year's 2.24 euros.

Underlying EBITDA was up 35.3 percent from last year to 488.7 million euros, and margin climbed to 29.1 percent from 26.6 percent a year ago.

In the first nine months, Sartorius increased Group sales revenue by 23.9 percent to 1.68 billion euros from 1.36 billion euros. Sales revenue grew 25.2 percent in constant currencies.

Order intake increased 36.3 percent on a reported basis and 37.8 percent at constant rates to 1.96 billion euros, with pandemic effects accounting for around 10 percentage points.

Looking ahead for fiscal 2020, Sartorius now expects consolidated sales revenue to increase at the upper end of, or slightly above, the range of 22 percent to 26 percent forecasted to date.

The underlying EBITDA margin is now forecasted to be around 29.5 percent, compared to previously expected about 28.5 percent.

Further, mid-range forecasts are subject to particularly high uncertainty at present, and has not changed its defined ambition for 2025. The company continues to expect to achieve sales revenue of around 4 billion euros and an underlying EBITDA margin of about 28 percent for the full year of 2025.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
PepsiCo, Inc. (PEP) has reached an agreement with private equity firm PAI Partners to sell Tropicana, Naked and other select juice brands across North America. The agreement also includes an irrevocable option to sell certain juice businesses in Europe. The combined pre-tax cash proceeds will be approximately... Drug major Eli Lilly And Co. reported Tuesday weak profit in its second quarter, despite higher revenues driven by strong volume across core business and most major geographies. Further, the company trimmed its forecast for fiscal 2021 earnings on a reported basis and margin, while maintained adjusted earnings view above market estimates. The company also tightened full-year revenue forecast. Shares of BMW Group were losing around 5 percent in German trading after the luxury automaker warned Tuesday that its second half-year is likely to be more volatile, affected by supply bottlenecks, high prices for raw materials and a shortage of semiconductors. This was despite reporting strong second-quarter results driven by solid demand.
RELATED NEWS
Follow RTT